Chevy Chase Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$159M Buy
205,833
+5,086
+3% +$3.89M 0.46% 36
2025
Q4
$155M Sell
200,747
-2,405
-1% -$1.63M 0.42% 38
2025
Q3
$114M Sell
203,152
-3,576
-2% -$2.02M 0.31% 61
2025
Q2
$109M Sell
206,728
-14,482
-7% -$8.08M 0.32% 59
2025
Q1
$140M Sell
221,210
-8,557
-4% -$5.89M 0.45% 38
2024
Q4
$164M Sell
229,767
-8,612
-4% -$7.23M 0.5% 34
2024
Q3
$251M Sell
238,379
-3,375
-1% -$3.76M 0.77% 18
2024
Q2
$254M Sell
241,754
-626
-0.3% -$607K 0.81% 17
2024
Q1
$233M Sell
242,380
-7,197
-3% -$6.84M 0.76% 19
2023
Q4
$219M Sell
249,577
-1,344
-0.5% -$1.11M 0.78% 18
2023
Q3
$206M Sell
250,921
-1,811
-0.7% -$1.42M 0.82% 18
2023
Q2
$182M Sell
252,732
-1,736
-0.7% -$1.34M 0.68% 25
2023
Q1
$209M Sell
254,468
-3,666
-1% -$2.76M 0.83% 17
2022
Q4
$186M Sell
258,134
-22,210
-8% -$16.4M 0.79% 21
2022
Q3
$193M Buy
280,344
+14,881
+6% +$9.37M 0.82% 19
2022
Q2
$157M Buy
265,463
+15,428
+6% +$10M 0.65% 29
2022
Q1
$175M Buy
250,035
+18,161
+8% +$11.5M 0.6% 30
2021
Q4
$146M Buy
231,874
+10,618
+5% +$6.53M 0.47% 42
2021
Q3
$134M Buy
221,256
+40,261
+22% +$25M 0.47% 45
2021
Q2
$101M Buy
180,995
+11,658
+7% +$5.91M 0.34% 64
2021
Q1
$80.1M Buy
169,337
+32,207
+23% +$15.7M 0.29% 86
2020
Q4
$66.3M Sell
137,130
-4,915
-3% -$2.65M 0.24% 97
2020
Q3
$79.5M Buy
142,045
+8,664
+6% +$5.25M 0.31% 78
2020
Q2
$83.2M Buy
133,381
+47,978
+56% +$27.2M 0.34% 70
2020
Q1
$41.7M Buy
85,403
+1,110
+1% +$458K 0.19% 121
2019
Q4
$31.7M Sell
84,293
-3,142
-4% -$1.06M 0.12% 184
2019
Q3
$24.3M Sell
87,435
-37,187
-30% -$11M 0.1% 218
2019
Q2
$39M Sell
124,622
-24,106
-16% -$8.03M 0.16% 143
2019
Q1
$51.6M Buy
148,728
+29,030
+24% +$12M 0.21% 109
2018
Q4
$44.7M Buy
119,698
+13,242
+12% +$4.85M 0.22% 106
2018
Q3
$43M Buy
106,456
+4,600
+5% +$1.75M 0.18% 130
2018
Q2
$35.1M Buy
101,856
+2,571
+3% +$804K 0.15% 155
2018
Q1
$34.2M Sell
99,285
-3,338
-3% -$1.16M 0.15% 158
2017
Q4
$38.6M Sell
102,623
-26,896
-21% -$10.9M 0.17% 142
2017
Q3
$57.9M Buy
129,519
+33,800
+35% +$16.1M 0.26% 99
2017
Q2
$47M Buy
95,719
+23,553
+33% +$10.3M 0.23% 111
2017
Q1
$28M Buy
72,166
+2,728
+4% +$1.01M 0.14% 177
2016
Q4
$25.5M Buy
69,438
+213
+0.3% +$81K 0.14% 179
2016
Q3
$27.8M Sell
69,225
-3,626
-5% -$1.45M 0.15% 159
2016
Q2
$25.4M Buy
72,851
+833
+1% +$321K 0.14% 167
2016
Q1
$26M Buy
72,018
+7,798
+12% +$3.21M 0.15% 158
2015
Q4
$34.9M Buy
64,220
+681
+1% +$369K 0.2% 119
2015
Q3
$29.6M Buy
63,539
+3,724
+6% +$2M 0.18% 133
2015
Q2
$30.5M Buy
59,815
+2,029
+4% +$990K 0.18% 144
2015
Q1
$26.1M Buy
57,786
+1,519
+3% +$644K 0.16% 163
2014
Q4
$23.1M Sell
56,267
-136
-0.2% -$53.5K 0.14% 177
2014
Q3
$20.3M Sell
56,403
-771
-1% -$258K 0.13% 186
2014
Q2
$16.1M Sell
57,174
-456
-0.8% -$135K 0.11% 209
2014
Q1
$17.3M Buy
57,630
+193
+0.3% +$59.5K 0.12% 198
2013
Q4
$15.8M Buy
57,437
+1,118
+2% +$322K 0.12% 202
2013
Q3
$17.6M Buy
56,319
+2,459
+5% +$647K 0.14% 170
2013
Q2
$12.1M Buy
+53,860
New +$12.5M 0.11% 221

Other funds holding REGN

Chevy Chase Trust's REGN Position: Q1 2026 in Review

Chevy Chase Trust increased its Regeneron Pharmaceuticals (REGN) stake by 2.5% in Q1 2026, buying an estimated $3.89M and bringing the position to 205,833 shares worth $159M. The position accounts for 0.46% of the portfolio, ranked #36.

Chevy Chase Trust first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $254M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Chevy Chase Trust held 205,833 shares of Regeneron Pharmaceuticals worth $159M as of Q1 2026.
  • Chevy Chase Trust bought 5,086 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.89M.
  • Regeneron Pharmaceuticals made up 0.46% of Chevy Chase Trust's portfolio in Q1 2026, its #36 holding.
  • Chevy Chase Trust first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Chevy Chase Trust's Regeneron Pharmaceuticals position peaked at $254M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Chevy Chase Trust's 13F filing for Q1 2026, filed 15 May 2026.